Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.